Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(16):1121-1123; doi:10.1093/jnci/djn261
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/16/1121    most recent
djn261v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Llovet, J. M.
Right arrow Articles by Lok, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Llovet, J. M.
Right arrow Articles by Lok, A.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma

Josep M. Llovet, Anna Lok

Affiliations of authors: Mount Sinai Liver Cancer Program, Department of Surgery, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY (JML); BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, Barcelona, Spain (JML); Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI (AL)

Correspondence to: Josep M. Llovet, MD, Director, HCC Research Program, Associate Professor of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, Madison Ave 1425. 11F-70. Box 1123, New York, NY10029 (e-mail: josep.llovet@mssm.edu).

The first 10% of the full text of this article appears below.

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death behind only lung and colon cancers (1) and the principal cause of death among cirrhotic patients (2). The incidence of HCC is increasing in the United States and Europe (3). Hepatitis B virus (HBV) infection affects 400 million people worldwide and is the main risk factor for HCC in Eastern Asia and Africa (4,5). Aflatoxin B exposure further enhances the risk of tumor development in HBV-infected patients. In Western countries and in Japan, hepatitis C virus (HCV) infection, which affects approximately 170 million people worldwide, is the most prevalent risk factor for HCC (4,5). Cirrhosis is the main risk factor . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
Hwai-I Yang, Shiou-Hwei Yeh, Pei-Jer Chen, Uchenna H. Iloeje, Chin-Lan Jen, Jun Su, Li-Yu Wang, Sheng-Nan Lu, San-Lin You, Ding-Shinn Chen, Yun-Fan Liaw, Chien-Jen Chen, and For the REVEAL-HBV Study Group
J Natl Cancer Inst 2008 100: 1134-1143. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 1119. [Extract] [Full Text] [PDF]